<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03574051</url>
  </required_header>
  <id_info>
    <org_study_id>Yunwei Wei 2018 -05-21</org_study_id>
    <nct_id>NCT03574051</nct_id>
  </id_info>
  <brief_title>the Microbiota Are Associated With Iodine-131 Therapy and Hypothyroidism</brief_title>
  <official_title>Distinct Shifts in the Microbiota Are Associated With Iodine-131 Therapy and Hypothyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Harbin Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thyroid cancer is a common neck malignancy. Currently, total thyroidectomy or subtotal
      thyroidectomy is the main method for the treatment of thyroid cancer patients. However, some
      thyroid cancer may still have residual thyroid tissue after operation. Therefore, in the
      differentiated thyroid In the treatment of cancer, iodine 131 treatment is mainly used
      because iodine 131 can emit high-energy beta rays, destroying the residual tissue of thyroid
      cancer and achieving good therapeutic goals. However, in the treatment of iodine-131, certain
      salivary glands are inevitably damaged, and the patient will have dry mouth symptoms. After
      the same treatment with iodine-131, some patients will experience gastrointestinal reactions
      such as nausea and vomiting. The therapeutic efficacy of iodine-131 depends on the lesion's
      uptake of iodine-131, which requires an increase in serum TSH levels. All patients in this
      study had stopped taking thyroid hormone for 3-4 weeks before iodine 131 treatment, making
      serum The TSH level is greater than 30 mU/L. At this time, the patient is in hypothyroidism.
      People with hypothyroidism experience dry mouth, dry skin, constipation, pain, cold, poor
      memory, depression, and weight gain. Many studies have pointed out that some cancer
      treatments, such as chemotherapy and radiotherapy, also have an impact on the microbial
      flora. However, studies on the relationship between microecology, hypothyroidism and
      iodine-131 treatment, probiotics in the prevention of hypothyroidism and iodine-131 treatment
      The link between the effects of side effects remains unclear. Therefore, the team will
      conduct a correlation study between microbes and hypothyroidism, iodine-131 treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thyroid cancer is a common neck malignancy and it mainly affects thyroid follicular cells or
      parafollicular cells. Thyroid cancer in various tumors in the body, the ratio can reach 1.2%
      to 2.3%. Thyroid cancer can be divided into differentiated thyroid cancer, squamous cell
      carcinoma, undifferentiated carcinoma, and medullary carcinoma, among which the incidence of
      differentiated thyroid carcinoma is more than 90%. At present, total thyroidectomy or
      subtotal thyroidectomy is the main method for the treatment of thyroid cancer patients, but
      some thyroid cancer may still have residual thyroid tissue after operation. Therefore, in the
      treatment of differentiated thyroid cancer, iodine 131 is mainly used. Treatment, because
      iodine 131 can emit high-energy beta rays, destroying the residual tissue of thyroid cancer,
      to achieve good therapeutic purposes. However, due to the presence of sodium iodine symporter
      in salivary glands and thyroid, it is inevitable that certain salivary glands will be damaged
      in the treatment of iodine 131, and patients will have dry mouth symptoms. Some patients with
      nausea 131 will also experience nausea and vomiting. Gastrointestinal reaction. Iodine 131
      treatment is divided into two steps: 1 removal of residual thyroid tissue; 2 removal of
      cancer lesions and metastases. The curative effect of 131I depends on the lesion's uptake of
      iodine-131, which requires an increase in serum TSH levels. All patients in this study had
      stopped taking thyroid hormone for 3 to 4 weeks before iodine-131 treatment. The TSH level is
      greater than 30 mU/L. At this time, the patient is in hypothyroidism. People with
      hypothyroidism experience dry mouth, dry skin, constipation, pain, cold, poor memory,
      depression, and weight gain. Many studies have pointed out that some cancer treatments, such
      as chemotherapy and radiotherapy, also have an impact on the microbial flora. However,
      studies on the relationship between microecology, hypothyroidism and iodine-131 treatment,
      probiotics in the prevention of hypothyroidism and iodine-131 treatment The link between the
      effects of side effects remains unclear. Therefore, the team will conduct a correlation study
      between microbes and hypothyroidism, iodine-131 treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of patients with improved side effects</measure>
    <time_frame>4 weeks</time_frame>
    <description>Improved side-effects in patients, such as reduced diarrhea and improved dry mouth symptoms</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Microbiota</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taking probiotics containing Bifidobacterium infantis, Lactobacillus acidophilus and Enterococcus faecalis for 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>Evaluate probiotics for preventing adverse effects of hypothyroidism and improvement of side effects caused by 131I treatment</description>
    <arm_group_label>Probiotic</arm_group_label>
    <other_name>Complex-probiotic-preparation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years old, 65 years old, male and female;

          -  Histologically confirmed differentiated thyroid cancer;

          -  After total thyroidectomy, patients who have undergone 131I therapy for the second
             time or more after recurrence or regional lymph node metastasis after 131I treatment
             for the first time are required. Or after the first 131I treatment, patients with
             differentiated thyroid who were treated with 131I for more than 3 months.

        Exclusion Criteria:

          -  Use of various antibiotics within three months;

          -  Having a history of alcoholism for more than 2 years and a history of smoking
             throughout the year;

          -  pregnancy or lactation;

          -  having oral, respiratory and gastrointestinal diseases;

          -  has a variety of metabolic diseases, such as obesity, hypertension, diabetes, stones,
             various liver diseases, etc.;

          -  having other autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis,
             inflammatory bowel disease, etc.;

          -  History of gastrointestinal surgery or other recent surgical history;

          -  Has a family history of genetic disease, mental illness, etc.;

          -  Research subjects are participating in other research topics;

          -  The researchers believe that other reasons are not suitable for continuing clinical
             trials;

          -  Undifferentiated thyroid cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yunwei Wei</last_name>
    <role>Study Director</role>
    <affiliation>First Affiliated Hospital of Harbin Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yunwei Wei</last_name>
    <phone>+86-0451-85553099</phone>
    <email>hydwyw11@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>First affiliated hospital of Harbin medical university</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunwei Wei</last_name>
      <phone>+86-0451-85553099</phone>
      <email>hydwyw11@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Verburg FA, HÃ¤nscheid H, Luster M. Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):279-290. doi: 10.1016/j.beem.2017.04.010. Epub 2017 May 9. Review.</citation>
    <PMID>28911724</PMID>
  </reference>
  <reference>
    <citation>Ciorba MA, Riehl TE, Rao MS, Moon C, Ee X, Nava GM, Walker MR, Marinshaw JM, Stappenbeck TS, Stenson WF. Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. Gut. 2012 Jun;61(6):829-38. doi: 10.1136/gutjnl-2011-300367. Epub 2011 Oct 24.</citation>
    <PMID>22027478</PMID>
  </reference>
  <reference>
    <citation>Linn YH, Thu KK, Win NHH. Effect of Probiotics for the Prevention of Acute Radiation-Induced Diarrhoea Among Cervical Cancer Patients: a Randomized Double-Blind Placebo-Controlled Study. Probiotics Antimicrob Proteins. 2019 Jun;11(2):638-647. doi: 10.1007/s12602-018-9408-9.</citation>
    <PMID>29550911</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2018</study_first_posted>
  <last_update_submitted>July 12, 2018</last_update_submitted>
  <last_update_submitted_qc>July 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oral microbiota</keyword>
  <keyword>16S rRNA gene</keyword>
  <keyword>thyroid cancer</keyword>
  <keyword>iodine 131 treatment</keyword>
  <keyword>fecal microbiota</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

